A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors.

MLA

Karim, Nagla Abdel, et al. “A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors.” Current Oncology (Toronto, Ont.), vol. 29, no. 12, Dec. 2022, pp. 9461–73. EBSCOhost, https://doi.org/10.3390/curroncol29120744.

APA

Karim, N. A., Ullah, A., Wang, H., Shoukier, M., Pulliam, S., Khaled, A., Patel, N., & Morris, J. C. (2022). A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors. Current Oncology (Toronto, Ont.), 29(12), 9461–9473. https://doi.org/10.3390/curroncol29120744

Chicago

Karim, Nagla Abdel, Asad Ullah, Hongkun Wang, Mahran Shoukier, Steven Pulliam, Ahmed Khaled, Nikhil Patel, and John C Morris. 2022. “A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors.” Current Oncology (Toronto, Ont.) 29 (12): 9461–73. doi:10.3390/curroncol29120744.